APT Therapeutics Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.58M

  • Investors
  • 4

APT Therapeutics General Information

Description

Developer of antiplatelet therapy designed for acute myocardial infarction, stroke and transplantation complications. The company's therapy uses protein engineering, protein informatics and cheminformatics software to create base therapeutics and molecule drugs for thrombotic diseases, enabling patients to get minimally damaged in case of a heart attack.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Saint Louis, MO
  • United States
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Saint Louis, MO
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

APT Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Grant 01-May-2023 $1.58M Completed Generating Revenue
11. Grant 20-Sep-2021 Completed Generating Revenue
10. Grant 15-Sep-2020 Completed Generating Revenue
9. Grant 18-Sep-2019 Completed Generating Revenue
8. Grant 18-Apr-2017 Completed Generating Revenue
7. Grant 18-Apr-2017 Completed Generating Revenue
6. Secondary Transaction - Private 27-Jan-2017 Completed Generating Revenue
5. Grant 01-Aug-2014 Completed Generating Revenue
4. Early Stage VC 01-Jan-2005 $3.68M Completed Startup
3. Early Stage VC 08-Jul-2004 $2.08M $3.68M Completed Startup
To view APT Therapeutics’s complete valuation and funding history, request access »

APT Therapeutics Patents

APT Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4114443-B1 Composition comprising apyrase and annexin that binds phosphatidylserine for treatment of arterial and venous thrombosis Active 06-Mar-2020
EP-4114443-C0 Composition comprising apyrase and annexin that binds phosphatidylserine for treatment of arterial and venous thrombosis Active 06-Mar-2020
ES-3062461-T3 Composition comprising apyrase and annexin that binds phosphatidylserine for treatment of arterial and venous thrombosis Active 06-Mar-2020
AU-2021230101-A1 Synergistic and targeting compositions for treatment of arterial and venous thrombosis Active 06-Mar-2020
AU-2021230101-B2 Synergistic and targeting compositions for treatment of arterial and venous thrombosis Active 06-Mar-2020 C12N9/14
To view APT Therapeutics’s complete patent history, request access »

APT Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
U.S. Department of Health and Human Services Government
CID Equity Venture Capital Minority
Prolog Ventures Venture Capital Minority
Nidus Center for Scientific Enterprise Accelerator/Incubator Minority
To view APT Therapeutics’s complete investors history, request access »

APT Therapeutics FAQs

  • When was APT Therapeutics founded?

    APT Therapeutics was founded in 2001.

  • Where is APT Therapeutics headquartered?

    APT Therapeutics is headquartered in Saint Louis, MO.

  • What industry is APT Therapeutics in?

    APT Therapeutics’s primary industry is Drug Discovery.

  • Is APT Therapeutics a private or public company?

    APT Therapeutics is a Private company.

  • What is APT Therapeutics’s current revenue?

    The current revenue for APT Therapeutics is .

  • How much funding has APT Therapeutics raised over time?

    APT Therapeutics has raised $3.68M.

  • Who are APT Therapeutics’s investors?

    U.S. Department of Health and Human Services, CID Equity, Prolog Ventures, and Nidus Center for Scientific Enterprise have invested in APT Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process